
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is positioned for future success due to its strong portfolio of royalty-generating assets and commitment to sustainability, as evidenced by reaffirming its revenue and earnings guidance and recent acquisition of XOMA. With the recent approval of FILSPARI, the company is expected to see continued revenue growth and has a raised valuation. While there are risks related to revenue sources and acquisitions, the company is taking proactive steps by engaging shareholders and employees in 2024.
Bears say
Ligand Pharmaceuticals is a biopharmaceutical company that relies heavily on partnerships and license agreements for revenue. However, the company faces risks such as the potential for competition, underperformance of pipeline drugs, and value-destructive deals. These factors, combined with the uncertainty surrounding the outcome of ongoing litigation and the acquisition of XOMA, contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares